Compare Anheuser-Busch Inbev SA (BUD) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Enveric Biosciences Inc — how do they compare? Anheuser-Busch Inbev SA trades at $78.98 (market cap $153.45B), while Enveric Biosciences Inc trades at $1.25 (market cap $5.32M). The key difference: Anheuser-Busch Inbev SA is far larger — about 28844× Enveric Biosciences Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.7% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| BUD | ENVB | |
|---|---|---|
Market Cap | $153.45B | $5.32M |
Sector | Consumer Staples | Health |
52-Week High | $85.09 | $17.40 |
52-Week Low | $57.10 | $1.28 |
Enterprise Value | $214.64B | $408.82K |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.33, down 0.35% with bearish technical signals. The company demonstrates solid fundamentals with consistent earnings beats, 11.9% net margin, and improving cash flow. Recent dividend payment of $1.17 and positive analyst sentiment with 57.8% buy ratings support the investment case. Premiumization strategy and digital expansion drive growth amid changing consumer preferences.
Outlook remains positive with $90.08 consensus price target offering 13.5% upside. Key risks include alcohol moderation trends and competitive pressures. Strong balance sheet with declining debt-to-asset ratio to 33.9% provides financial stability. Revenue growth expected to accelerate to $61B in 2026 with expanding margins.
ENVB trades at $1.33, down 1.48% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows significant financial challenges with negative ROE of -257.95% and ROA of -218.01%, though it has consistently beaten earnings expectations in recent quarters. Recent news highlights active participation in investor conferences and progress with EB-003 drug candidate development.
While analyst consensus is 75% buy-rated, the stock faces substantial fundamental risks from negative profitability and cash burn. Investment opportunity exists if clinical developments succeed, but shareholders should weigh high operational losses against potential biotech breakthroughs in the neuroplastogenic therapeutics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
